Necrotic Enteritis Treatment Market Size, Share, and Industry Analysis, By Drug Type (Probiotics, Antibiotics, and Others), By Animal Type (Chickens, Turkeys, Ducks, and Others), By Distribution Channel (Veterinary Hospital & Clinic Pharmacies, Veterinary Retail Pharmacies, and Veterinary Online Pharmacies), and Regional Forecast, 2025-2032

The necrotic enteritis treatment market is witnessing significant growth owing to the growing prevalence and rising awareness about this disease. Necrotic enteritis is an infection that mainly affects poultry animals. It is caused by the overgrowth of the Clostridium perfringes bacteria in the intestines of poultry animals. The bacteria is generally rod-shaped Clostridium, which produces pores that can cause dryness or acidity. Necrotic enteritis is a multifactorial disease.

Several components must occur simultaneously for the Clostridium to begin multiplying in large numbers and producing toxins (a-Toxin and Net-b) that harm the intestine. The disease normally occurs after infection with Eimeria parasites, especially when birds are fed diets containing grains that promote high intestinal viscosity, such as wheat, barley, and rye. Necrotic enteritis is commonly seen in broiler chicken, however layers and turkeys are also affected by the condition.

Treatment options include antibiotics and dietary supplements, which are used to control the disease in poultry animals, specifically chicken and turkey.

• According to data published by the National Center for Biotechnology Information (NCBI) in September 2022, the prevalence of necrotic enteritis in Denmark was reported in one to two out of 1700 farms.
• According to data published by the South Asian Research Journal of Biology and Applied Biosciences (SARB) in April 2022 in Bangladesh, necrotic enteritis was found at the highest rate (11.67%) in the winter season.

Necrotic Enteritis Market Driver

Growing Demand for Poultry Animals Has Been Fueling Market Growth

The prevalence of necrotic enteritis has been growing significantly, fueling the demand for effective treatment options. Necrotic enteritis is commonly seen in 2 to 5 week-old broiler chickens. Therefore, the increasing prevalence of necrotic enteritis and the rising demand for effective treatment have been driving the growth of the necrotic enteritis treatment market.

• According to data published by the South Asian Research Journal of Biology and Applied Biosciences in April 2022, in Bangladesh, the overall prevalence of necrotic enteritis in chickens was about 7.84%. According to data published by the South Asian Research Journal of Biology and Applied Biosciences in April 2022, in Rajshahi District, Bangladesh, the incidence of necrotic enteritis was approximately 1.5 times higher in broiler chickens (9.6%) compared to Sonali chickens (6.2%).

Download Free sample to learn more about this report.

According to data published by Elsevier Inc. in November 2021, 58% of poultry birds in the U.S. were suffering from necrotic enteritis, 61% in the U.K., and 70% in Australia.

Necrotic Enteritis Market Restraint

Occurrence of Antibiotic Resistance in Animals May Limit the Adoption of Therapeutics

The emergence of antibiotic-resistant Clostridium perfringens bacteria can lead to necrotic enteritis and pose a significant problem. Antibiotic resistance occurs when bacteria change to resist antibiotics that were once effective in treating them, making certain bacterial infections difficult to treat. Due to this, the poultry farm owners avoid spending on the treatment for necrotic enteritis, as there would be no improvement in the animals condition. This factor has been limiting the adoption of effective treatment option, thereby restricting the market growth.

• According to data from a research study published by the National Center for Biotechnology Information (NCBI) in September 2022, 9.5% of the 269 chickens in Thailand were found to be resistant to metronidazole. It was concluded that antibiotic resistance causes a major hindrance to treating animals.

Necrotic Enteritis Market Opportunity

Necrotic enteritis has a wide range of emerging, high growth markets, especially in developing regions. Therefore, there has been a growing interest in using probiotics and prebiotics as a treatment for necrotic enteritis, as these bacteria are beneficial for gut health.

• According to data from the National Center for Biotechnology Information (NCBI) in September 2022, probiotics (30%) and prebiotics (29%) reduced mortality due to necrotic enteritis to a level comparable to that of in-feed antibiotics, concluding that the use of prebiotics and probiotics could fuel the growth of necrotic enteritis treatment.

Key Insights

The report covers the following key insights:

• Incidence of Necrotic Enteritis, By Key Countries, 2023
• Overview: Poultry Population, By Key Countries, 2023
• Overview: Regulatory Scenario, Veterinary Therapeutics, By Key Countries
• Key Industry Developments (Mergers, Acquisitions, Partnerships)
• Impact of COVID-19 on the Market

Segmentation

Analysis by Drug Type

By drug type, the market for necrotic enteritis treatment is segmented into probiotics, antibiotics, and others.

The antibiotic segment accounted for a significant market share in 2023. The segment growth is attributed to the efficacy of these therapeutics. Moreover, poultry farm owners mix these antibiotics in animal food for better treatment

• According to data published by the National Council of Biotechnology (NCBI) in 2019, it was reported that 73% to 80% of all antibiotics sold worldwide were used specifically for food animal production.

Analysis by Animal Type

By animal type, the market for necrotic enteritis treatment is categorized into chickens, turkeys, ducks, and others.

The chickens segment accounted for a significant market share in 2023. The segment growth can be attributed to the overgrowth of Clostridium perfringens type A and C in their intestines. As a result, chickens are more prone to necrotic enteritis compared to other poultry animals.

Analysis by Distribution Channel

By distribution channel, the market is segmented into veterinary hospital & clinic pharmacies, veterinary retail pharmacies, and veterinary online pharmacies.

The veterinary hospital & clinic pharmacies segment accounted for a significant market share. The segment growth is attributed to the

Regional Analysis

To gain extensive insights into the market, Download for Customization

By region, the market has been studied across North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

The necrotic enteritis treatment market in North America holds a significant share, driven by the awareness of the prevalence of necrotic enteritis. Companies based in the U.S., such as Kemin and Merck, also contribute to the increasing prevalence in this region.

• According to data published by Elsevier Inc. in 2021, necrotic enteritis impacted around 58% of chickens in U.S. poultry farms.

The Europe market is expected to grow significantly due to the growing burden of necrotic enteritis and the rising demand for effective treatment in the region. The growth is also attributed to the reduction of antibiotics in farming. The absence of antibiotics allows for the overgrowth of Clostridium per-fringes, a primary pathogen responsible for necrotic enteritis. The number of bacteria present in the gut increases without antibiotics.

• According to data published by the National Council of Biotechnology (NCBI) in September 2022 in Europe, of the 75 respondents, 32.8% reported a case of necrotic enteritis in at least one flock.

The necrotic enteritis treatment market in Asia Pacific holds a significant share, driven by the increasing incidence of necrotic enteritis in poultry during the monsoon and winter seasons due to relatively higher humidity, which can cause various infections in animals.

• According to data published by the Indian Veterinary Journal in October 2020 in Assam, the number of positive cases of necrotic enteritis was the highest, 21 out of 337, followed by the winter season.

Key Players Covered

The market for necrotic enteritis treatment is fragmented, with the presence of small and mid-sized companies. The report includes the profiles of the following key players:

• Kemin Industries, Inc. (U.S.)
• Merck & Co., Inc. (U.S.)
• Bio Gaia (Sweden)
• Phibro Animal Health corporation (U.S.)
• Biomin (Austria)
• Advacare (U.S.)
• Elanco (U.S.)
• Huvepharma (Bulgaria)
• Zoetis (U.S.)

Key Industry Developments

• In April 2024, Huvepharma Inc. received a license for a new coccidiosis vaccine to treat necrotizing enteritis in Turkey.
• In April 2024, Kemin Industries, Inc. announced that the company’s brand of CLOSTAT, which is a probiotic had celebrated two decades of presence in the global market. CLOSTAT is administered to the poultry and livestock for the management of intestinal health to effectively support the microbiota of the animal and to curtail the development of clostridia.